Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Notes underwriting agrmnt
Inv. presentation
PRECIGEN, INC. (XON) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025",
"Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval"
07/06/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/09/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "Precigen Reports First Quarter 2023 Financial Results and Business Updates"
04/25/2023 ARS Form ARS - Annual Report to Security Holders:
04/25/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/25/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
03/06/2023 10-K Annual Report for the period ended December 31, 2022
03/06/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates"
01/31/2023 SC 13D/A KIRK RANDAL J reports a 38.3% stake in PRECIGEN, INC.
01/27/2023 SC 13G/A Ares Trading S.A. reports a 9.9% stake in Precigen, Inc.
01/27/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "PRECIGEN, INC. 42,857,143 Shares of Common Stock Underwriting Agreement",
"Company”), in connection with its registration statement on Form S-3, as amended , filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended relating to the proposed public offering of up to 49,285,714 shares of the common stock, no par value per share, of the Company , all of which shares are to be sold by the Company pursuant to the Underwriting Agreement dated January 24, 2023 between the Company and J.P. Morgan Securities LLC as Representative of the several Underwriters named in Schedule 1 thereto , as described in the prospectus, dated July 2, 2020, that forms part of the Registration Statement , as supplemented by the Prospectus Supplement, dated January 24, 2023 (together with the Registration Statement Prospectus, the “Prospectus"
01/24/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
01/24/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse ™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis"
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/09/2022 8-K Quarterly results
10/07/2022 SC 13D/A KIRK RANDAL J reports a 40.7% stake in PRECIGEN, INC.
09/21/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Precigen Names Rutul R. Shah Chief Operating Officer"
08/24/2022 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "Unaudited Pro Forma Consolidated Financial Information"
08/22/2022 8-K Quarterly results
08/09/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Sales Agreement",
"Exhibits 5.1 and 23.1 Hogan Lovells US LLP Harbor East 100 International Drive Suite 2000 Baltimore, MD 21202 T +1 410 659 2700 F +1 410 659 2701 www.hoganlovells.com August 9, 2022 Board of Directors Precigen, Inc. 20374 Seneca Meadows Parkway Germantown, MD 20876 To the addressee referred to above: We are acting as counsel to Precigen, Inc., a Virginia corporation , in connection with its registration statement on Form S-3, as amended , filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended , relating to the issuance and sale of up to $100,000,000 of shares of common stock, no par value, of the Company from time to time and at various prices in an “at the market offering” pursuant to the terms of the Controlled Equity Offering SM Sales Agreement, d..."
08/09/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/08/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/08/2022 8-K Quarterly results
07/13/2022 8-K Quarterly results
07/05/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
05/09/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/09/2022 8-K Quarterly results
04/29/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/29/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy